Characterization of human non-small cell lung cancer (NSCLC) cell lines for expression of MHC, co-stimulatory molecules and tumor-associated antigens

被引:45
作者
Wroblewski, JM
Bixby, DL
Borowski, C
Yannelli, JR
机构
[1] Univ Kentucky, Coll Med, Markey Canc Ctr, Div Hematol & Oncol, Lexington, KY 40536 USA
[2] Univ Kentucky, Coll Pharm, Dept Med Chem & Pharmaceut, Lexington, KY 40536 USA
[3] Harvard Univ, Sch Med, Dept Immunol, Boston, MA USA
关键词
non-small cell lung cancer; CD80; CD86; cytotoxic T cells; immunotherapy;
D O I
10.1016/S0169-5002(01)00210-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A panel of 31 long-term non-small cell lung cancer (NSCLC) cell lines was examined for the expression of protein and/or mRNA transcripts for 11 distinct immune response related molecules or tumor associated antigens (TAA). To assess whether cytokine stimulation might up-regulate expression of the genes of interest, cells were cultured in 500 U/ml of gamma-interferon (gamma -IFN) for 48-72 h prior to analysis. Major histocompatibility complex (MHC) Class I antigens were detected by indirect immunofluorescence and were constitutively expressed on all of the cell lines. The average of the mean fluorescence intensity (MFI) measured 222 +/- 22. gamma -IFN stimulation produced a significant increase to 482 +/- 36. For MHC Class II only 7/31 cell lines (23%) exhibited constitutive expression, while gamma -IFN treatment had a dramatic effect and yielded 18/31 (58%) positive cell lines. The co-stimulatory molecules CD80 and CD86 were examined by direct immunofluorescence for cell surface expression and RT-PCR amplification for mRNA. CD80 protein was not detected at all, while an insignificant percentage of cells were positive (mean 2%) for CD86 in all cell lines tested. gamma -IFN had no apparent effect on CD80 or CD86 protein expression. Constitutive CD80 or CD86 mRNA levels were observed in 45 and 61% of the NSCLC lines, respectively. These percentages increased to 77% and 90% with gamma -IFN. Cell surface phenotypic analysis for TAA revealed positive populations in 28/31 cell lines (90%) for Her-2/neu, 18/31 (58%) for CEA and 8/31 (26%) for GD-2, with gamma -IFN having no effect. After gamma -IFN stimulation, RT-PCR amplification for Mage-1, -2, -3 and WT-1 detected mRNA in 33%, 33%, 44% and 70% of the cell lines, respectively. Overall, gamma -IFN stimulation led to the up-regulation of MHC Class I molecules and class 11 molecules as well as CD80 and CD86 mRNA transcripts. This survey represents the first comprehensive analysis of NSCLC cell lines for a variety of molecules that could play an important role in the generation of an NSCLC anti-tumor CD8 + cytotoxic T lymphocyte (CTL) response. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:181 / 194
页数:14
相关论文
共 54 条
[11]  
Foon KA, 1998, CLIN CANCER RES, V4, P1117
[12]   Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells [J].
Gabrilovich, DI ;
Chen, HL ;
Cunningham, HT ;
Meny, GM ;
Nadaf, S ;
Kavanaugh, D ;
Carbone, DP .
NATURE MEDICINE, 1996, 2 (10) :1096-1103
[13]  
GAZDAR AF, 1986, CANCER RES, V46, P6011
[14]   CELL-CULTURE METHODS FOR HUMAN-LUNG CANCER [J].
GAZDAR, AF ;
OIE, HK .
CANCER GENETICS AND CYTOGENETICS, 1986, 19 (1-2) :5-10
[15]   Frequency of MAGE-3 gene expression in HLA-A2 positive patients with non-small cell lung cancer [J].
Gotoh, K ;
Yatabe, Y ;
Sugiura, T ;
Takagi, K ;
Ogawa, M ;
Takahashi, T ;
Takahashi, T ;
Mitsudomi, T .
LUNG CANCER, 1998, 20 (02) :117-125
[16]  
Harpole DH, 1995, CLIN CANCER RES, V1, P659
[17]   EXPRESSION OF THE COSTIMULATORY MOLECULE B7 ON MELANOMA-CELLS [J].
HERSEY, P ;
SI, ZY ;
SMITH, MJ ;
THOMAS, WD .
INTERNATIONAL JOURNAL OF CANCER, 1994, 58 (04) :527-532
[18]   PGP9.5 as a candidate tumor marker for non-small-cell lung cancer [J].
Hibi, K ;
Westra, WH ;
Borges, M ;
Goodman, S ;
Sidransky, D ;
Jen, J .
AMERICAN JOURNAL OF PATHOLOGY, 1999, 155 (03) :711-715
[19]  
Hsieh CC, 1998, ANN THORAC SURG, V66, P1159, DOI 10.1016/S0003-4975(98)00792-9
[20]  
Iezzi G, 1996, CANCER RES, V56, P11